Research
Metabolic adaptation
Tirzepatide increases insulin secretion, reduces glucagon release, decreases fasting and postprandial glucose levels, promotes satiety, decreases body weight, and delays gastric emptying.
Tirzepatide can help manage blood sugar levels and weight in patients with type 2 diabetes.
StrongSupportsmedium confidence
Tirzepatide increases insulin secretion, reduces glucagon release in a glucose-dependent manner, decreases fasting and postprandial glucose levels, promotes satiety, decreases body weight, and delays gastric emptying.
Why this rating
Supported by clinical trial data mentioned in the abstract.
Source
Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus
Elaine Wong et al. · American Journal of Therapeutics · 2022
DOI 10.1097/mjt.0000000000001588
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide is a first in class dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP) analog approved for the management of adult patients with type 2 diabetes mellitus.Strong
- Tirzepatide consistently showed reductions in HbA1c and benefits with weight loss in clinical trials.Strong
Related findings · Metabolic adaptation
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →